GT Biopharma, Inc. (GTBP) Total liabilities 2016–2020
GT Biopharma, Inc. (GTBP) total liabilities at each fiscal year-end, per SEC filings.
$35.1MFY2020 · since FY2016: $18.9M → $35.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2020 | $35.1M | +78.1% |
| FY2019 | $19.7M | — |
| FY2017 | $2.7M | -85.9% |
| FY2016 | $18.9M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More GTBP financial trends
GTBP RevenueGTBP Net incomeGTBP Net marginGTBP Gross profitGTBP Gross marginGTBP Operating incomeGTBP Operating marginGTBP Operating cash flowGTBP Free cash flowGTBP Capital expendituresGTBP Return on equityGTBP Stock buybacksGTBP Dividends paidGTBP Total assetsGTBP Shareholders’ equityGTBP overview →